← Evidence library

BIB_452

Sex differences in melanoma immunotherapy (anti-PD-1/CTLA-4) efficacy & toxicity — CONTINGENCY literacy only, distinct from BIB426 (male-sex localised-disease prognostic decrement). Kudura 2022 (Cancers, n=103 advanced melanoma on ICI): men significantly better short/long-term response (OS p=0.015, PFS p<0.001); women more frequent IRAEs. Reproducible direction across cohorts + meta (Bilani 2025; Conforti-type meta) but heterogeneous magnitude. CRITICAL: sex is a prognostic modifier, NOT a treatment-selection criterion — ICI indicated regardless of sex; reject the small-study "use ICI carefully in women" over-reach. For this male Stage IB patient: only mildly reassuring IF ever upstaged to I

Evidence grade

C

Tier

2 (multiple cohorts + meta-analyses incl. landmark sex-ICI meta; retrospective/o

Cited by tasks

18, 22a, 23

Identifiers

PMC9600302

↗ Follow the original source for full context

Full extracted findings & patient-implication analysis: bibliography/BIB_452/findings.md (research corpus). This page is a short context summary — not individualised medical advice.